RxDoctor Payments Data

Rudolph Acosta, MD

Urology · Tampa, FLNPI 1285645564

Payments from drug & device makers

$3,243in general payments, 2019–2025

Across 148 payments — averaging $21.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$805
  • Bayer$261
  • Coloplast$246
  • Pfizer$232
  • Antares Pharma, Inc.$195
  • Axonics, Inc.$154
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$3,243100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,243 in reported general payments places this provider in the 40th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$82,466
Medicare patients
277
Services billed
1,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron56$36,700
GemtesaVibegron21$14,008
Testosterone Cypionate92$6,795
Finasteride389$5,152
Tamsulosin Hcl297$3,489
Solifenacin Succinate81$3,411
Testosterone16$3,330
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst119$3,094
Estradiol21$1,099
Doxazosin Mesylate33$878
Bicalutamide24$764
Potassium Citrate ErPotassium Citrate11$747
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav32$644
Alfuzosin Hcl ErAlfuzosin Hcl13$450
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim49$278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$135$36,70056 claims
Sumitomo Pharma America, Inc.Gemtesa$76$14,00821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 935 urology providers in Florida.

Other urology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →